US pharmaceutical company AstraZeneca Plc (LON: AZN) (STO: AZN) announced on 23 November 2020 that its experimental COVID-19 vaccine has shown an average efficacy of 70% in its large scale trials, CNN reported on Monday.
This vaccine, developed with the University of Oxford, showed 90% efficacy in one dosing regimen and 62% efficacy in a second regimen, which averages to a 70% efficacy, AstraZeneca said.
In a news release, AstraZeneca said that its vaccine was "highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine."
According to the company, the interim analysis included a total of 131 COVID-19 cases.
This comes after Moderna announced earlier this month that its vaccine was 94.5% effective against COVID-19 and Pfizer announced its vaccine was 95% effective, CNN added.
Valneva expects UK rollout of COVID-19 vaccine to start in July to September 2021
Dr. Reddy's Laboratories to begin phase 3 study of Sputnik V vaccine in India
Jubilant Therapeutics collaborates with The Wistar Institute
Brazil's health regulator clears emergency use of Sinovac and AstraZeneca COVID-19 vaccines
England opens up its COVID-19 vaccination programme to more groups
Dr. Reddy's Receives Approval to Conduct Phase 3 Clinical Trial for Sputnik V Vaccine in India
Carbon Health Launches COVID-19 Vaccination Platform to Accelerate National Rollout
Kyruus Enables Online Scheduling for COVID-19 Vaccine Visits
China's Sinopharm says COVID-19 vaccine safe for children and teenagers
Publix and the State of Florida to Bring COVID-19 Vaccinations to Three Florida Counties
OnSolve's CodeRed used across the US for the management of information related to COVID-19 vaccine
Meijer Pharmacies to administer COVID-19 vaccines in the State of Michigan